Treatment of Primary Ovarian Lymphoma in Classic Hodgkin Lymphoma, Stage I–II, Favourable (No Risk Factors)

Clinical Scenario

This protocol addresses primary ovarian lymphoma classified as classic Hodgkin lymphoma (cHL), presenting at stage I–II with a favourable profile and no identified risk factors.

Treatment Approach

The standard of care for this favourable-risk presentation combines a short course of combination chemotherapy with involved-site radiation therapy. The complete regimen — including sequencing, agents, and dosing — is detailed in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.annonc.2025.07.014

For patients with favourable classic HL (cHL), the SoC is two cycles of doxorubicin—bleomycin—vinblastine—dacarbazine (ABVD) [I, A] followed by 20 Gy ISRT [I, A].

View source ↗